Historic VEGF inhibitors in lung cancer improved progression-free survival without yielding overall survival gains. The phase 3 HARMONY-6 trial broke this pattern by showing a statistically and clinically significant median overall survival improvement of 27 versus 23 months (hazard ratio 0.66) when combining ivonescimab with chemotherapy.
Frontline VEGF inhibition was historically avoided in squamous non-small cell lung cancer due to severe bleeding risks. In the HARMONY-6 study, excluding patients with large cavitary lesions or significant hemoptysis kept severe grade 3 or higher hemorrhage and arterial thromboembolism uncommon.
Patients with EGFR-mutated lung cancer progressing on frontline TKIs frequently exhibit CNS metastases and historically respond poorly to checkpoint inhibitors. In the HARMONY trial, adding ivonescimab to chemotherapy preserved progression-free survival benefits and actually produced greater additive benefit in patients presenting with brain metastases.
Although ivonescimab plus chemotherapy demonstrates efficacy following EGFR-TKI failure, oncologists display little consensus regarding its treatment line placement. Increased frontline chemotherapy usage from regimens like FLAURA2 creates sequencing dilemmas regarding whether bispecifics belong in the second line or should be reserved for later lines.
Simultaneous targeting of VEGF and checkpoint inhibition raised concerns regarding compounded toxicities, but clinicians view the side-effect profile as familiar. Polling and trial results suggest ivonescimab's VEGF-related toxicities remain mostly low grade and are comparable to or more manageable than historical monoclonal antibodies like bevacizumab.
